Prime Medicine Future Growth
Future criteria checks 2/6
Prime Medicine's earnings are forecast to decline at 7.6% per annum while its annual revenue is expected to grow at 29.6% per year. EPS is expected to grow by 5.2% per annum. Return on equity is forecast to be -99.4% in 3 years.
Key information
-7.6%
Earnings growth rate
5.2%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 29.6% |
| Future return on equity | -99.4% |
| Analyst coverage | Good |
| Last updated | 12 Apr 2024 |
Recent future growth updates
Recent updates
Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25
We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 14 | -256 | -259 | -276 | 4 |
| 12/31/2025 | 11 | -224 | -226 | -219 | 5 |
| 12/31/2024 | 16 | -216 | -195 | -156 | 6 |
| 12/31/2023 | N/A | -198 | -174 | -165 | N/A |
| 9/30/2023 | N/A | -173 | -164 | -152 | N/A |
| 6/30/2023 | N/A | -158 | -157 | -143 | N/A |
| 3/31/2023 | N/A | -151 | -139 | -123 | N/A |
| 12/31/2022 | N/A | -142 | -148 | -132 | N/A |
| 9/30/2022 | N/A | -171 | -126 | -114 | N/A |
| 6/30/2022 | N/A | -158 | -103 | -94 | N/A |
| 3/31/2022 | N/A | -126 | -85 | -80 | N/A |
| 12/31/2021 | N/A | -184 | -38 | -34 | N/A |
| 9/30/2021 | N/A | -118 | -27 | -23 | N/A |
| 12/31/2020 | 5 | -5 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRME's revenue (29.6% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: PRME's revenue (29.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRME is forecast to be unprofitable in 3 years.